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ABSTRACT
Mathematical Modeling of Immune Responses to Hepatitis C Virus Infection
by
Ivan Ramirez
An existing mathematical model of ordinary differential equations was studied to
better understand the interactions between hepatitis C virus (HCV) and the immune
system cells in the human body. Three possible qualitative scenarios were explored:
dominant CTL response, dominant antibody response, and coexistence. Additionally,
a sensitivity analysis was carried out to rank model parameters for each of these
scenarios. Therapy was addressed as an optimal control problem. Numerical solutions
of optimal controls were computed using a forward-backward sweep scheme for each
scenario. Model parameters were estimated using ordinary least squares fitting from
longitudinal data (serum HCV RNA measurements) given in reported literature.
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1 BASIC BACKGROUND
1.1 Hepatitis C Virus
Hepatitis C, which is an infectious liver disease caused by the hepatitis C virus
(HCV), is commonly transmitted through direct contact with the blood of an in-
fected person (blood transfusion, injection drug use, etc). About 150 million people
worldwide are chronically infected with hepatitis C virus, and more than 350,000
people die every year from hepatitis C-related liver diseases [28]. After exposure to
HCV, a strong host immune response is launched. However, in a majority of pa-
tients the response fails to eradicate the virus, leading to chronic infection [14]. As a
matter of fact, HCV is a major cause of chronic liver cirrhosis and liver cancer [28].
Antiviral medicines such as combinations of pegylated-interferon−α and ribavirin
(PEG-INF/RBV) have been used as medication for several years. Nevertheless, this
treatment is far from being ideal, it is associated with significant side effects, is expen-
sive, and only has a cure rate of 50% or less in patients infected with HVC genotype
1 [6, 12, 14]. More recently treatments are focused on direct-acting antiviral agents
(DAAs) that target specific steps of the HCV life cycle. More details about these
new types of treatments can be found in [24, 11, 23]. There is currently no vaccine
for hepatitis C virus. Nevertheless, research in this area is outgoing.
In this thesis we want to understand the interactions between the hepatitis C
virus and the immune system. For this reason it is necessary to understand the
characteristics of the immune responses against foreign pathogens.
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1.2 Immune Responses
The immune system is an organization of cells, organs, and molecules that protect
the body from infection. The purpose of the immune system is to defend the body
against foreign pathogens such as certain bacteria, viruses, and fungi. There are
two fundamental categories of immune responses against invading pathogens [8, 26]:
(i) innate or nonspecific responses, and (ii) specific or adaptive responses. Innate
immune responses form a first barrier to protect the body against infection. Immune
cells such as macrophages and natural killer cells are examples of cells that fight
pathogens in a nonspecific way. In other words, these type of responses act as reactions
of the body against an invader, no matter what type of pathogen they are fighting.
Skin, coughing, sneezing, and fever are also examples of the nonspecific immune
responses. The adaptive responses are due to cells and molecules that are able to
recognize the physical structure of a pathogen [26]. They can perceive proteins from
which the pathogen is built. Once these cells are activated they start to divide
and expand in number. Probably the most important component of the specific
immune system are the lymphocytes. These type of cells are white blood cells that
arise continuously in the bone marrow (flexible tissue in the interior of the bones).
One microlitre of human blood contains about 2500 lymphocytes and in total there
are about 1012 lymphocytes in an adult human [20]. Lymphocytes can be grouped
into two major branches: B-lymphocytes, referred to as B cells, and T-lymphocytes,
referred to as T cells [8, 20, 21, 26].
B cells carry antibody molecules on their surface membrane that serve as receptors
that can specifically recognize the pathogen [8, 20, 26]. During B cell development,
14
the immune system creates billions of different antibodies with a limited number of
genes by rearranging DNA segments. Mutation can also increase genetic variation
in antibodies. Basically, for any pathogen that enters the body, there is a specific
antibody molecule that can recognize it [20].
When HCV enters the human body, most B-cells do not have the specific receptors
to recognize this foreign intruder. However, some B-cells will be able to bind some
viral proteins. There is a specific antibody molecule that can bind to the pathogen in
a lock-and-key system manner. Once a B-cell is bound to the virus particle, a process
known as endocytosis starts. In this process, the virus is broken into pieces and part
of it is presented in association with the so-called major histocompability complex
type II (MHC II), which is a molecule on the surface of the B-cell [8, 20, 26].
T-helper cells or CD4 cells are another type of T-cells that play an important role
in the activation of B-cells. If CD4 cells can bind the presented part of the virus on
the surface of the B-cell, a release of molecules will occur and the activation of the
B-cell will be complete [20].
Once B-cells are activated they start to divide into memory and effector cells.
This production of new B-cells are replications with the same specific receptor that
can recognize HCV. The memory B-cells will take no action but stay in the system
in case this pathogen enters the host in the future [20, 26]. The effector B-cells, also
called plasma cells, are responsible in the release of new antibodies. These antibodies
then bind to the virus particles and tag them as foreign pathogens for elimination by
a macrophage [20].
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T cells can be grouped into two types of cells: T helper cells or CD4 and cytotoxic
T lymphocytes (CTL) or CD8. The acronyms CD4 and CD8 refer to some proteins
on the surface of these cells [20, 26]. As we mentioned above, T helper cells play
an important role in the activation of the B-cells and therefore in the release of
antibodies. The CTL have the ability to take lytic action against infected cells by
killing them. These cells can recognize and eliminate infected cells. Once a cell has
been infected it becomes a factory of production of new virus. The viral proteins
inside the infected cell are presented on the surface in combination with the major
histocompability complex type I (MHC I), which is presented essentially in every cell
of the human body. If a specific CTL with the correct T-cell receptor can recognize
this presented portions on the surface of the infected cells then it will bind to the
cell. The CD8 cell will become activated and start to produce chemicals that kill the
target cell [20]. After activation, the CTL will proliferate into effector and memory
cells, much like in the B-cell activation process. The effector cells will have the same
functions as the parent cell: to destroy infected cells while the memory cells will
stay in the host in case of a future infection. A schematic illustration of the types
of immune responses can be found in Figure 1. A summarized explanation of the
dynamics of the immune system is shown in Figure 2.
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Figure 1: Schematic illustration of the two types of immune responses: the innate and
the adaptive responses. The most important compartment of the adaptive responses
are the lymphocytes that can be grouped into B-cells and T-Cells.
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Figure 2: Schematic illustration of the adaptive and innate responses. The adaptive
responses can be grouped into B-cells and T-cells. The B-cells secrete antibodies that
neutralize free virus particles. The cytotoxic T lymphocytes (CTLs or CD8) eliminate
infected cells. The CD4 T helper cells ensure that CTLs and B-cells develop efficiently.
Phagocytes are cells in charge of eliminating virus particles that have been bound by
antibodies.
18
The interactions between immune responses and pathogens can be considered a
predator-prey system. The virus is the prey and the immune cells like the B-cells
and T-cells are the predators. In the absence of the pathogen, the immune cells
die. The predator species that is most efficient at capturing the prey can reduce the
food resource to levels which are too low for other predator species to survive. This
can result in competitive exclusion where only one predator species remains [27]. If
antibodies are more efficient at fighting a virus, they can reduce virus load to levels
that are too low to stimulate the CTLs. This outcome is going to be called a dominant
antibody response. Likewise, if CTLs are more efficient in killing the pathogen, they
can reduce the virus load to levels that are too low to stimulate the antibodies. This
outcome is called a dominant CTL response. In addition to these exclusion outcomes,
there is also a coexistence outcome. Even if the CTLs are very efficient in reducing the
number of infected cells, the number of viruses could be sufficiently large to stimulate
the antibody response. More details about immunity can be found in [20, 26].
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2 MATHEMATICAL MODEL
In literature, several models have been used to describe HCV dynamics [19, 6, 25].
The following model, proposed by Wodarz [25], describes the competition dynamics
between CTL and antibodies as responses to a viral infection. In particular, this
model can be used to study the interaction between HCV and immune responses in
a host. We denote the number of uninfected hepatocytes (cells of the liver), at time
t, by T (t), infected hepatocytes by I(t), the viral load by V (t), the number of CTLs
by Z(t), and the number of antibodies by W (t). The system of differential equations
that describes the change of these populations over time is:
dT
dt
= s− dT − βV T (1)
dI
dt
= βV T − aI − pIZ (2)
dV
dt
= kI − µV − qV W (3)
dZ
dt
= cIZ − bZ (4)
dW
dt
= gV W − hW (5)
This model assumes uninfected host cells (healthy hepatocytes) are produced at
a rate s, undergo natural decay at a rate dT and become infected by the interaction
with virus at a rate βTV . Infected cells die at a rate aI and are killed by the CTL
response at a rate pIZ. Free virus is produced by infected cells at a rate kI, decays at
a rate µV and is neutralized by antibodies at a rate qV W . CTL expand in response
to viral antigen derived from infected cells at a rate cIZ and decay in the absence of
antigenic stimulation at a rate bZ. Antibodies develop in response to free virus at a
rate gV W and decay at a rate hW .
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2.1 Qualitative Scenarios
Definition 2.1 The basic reproductive number of the virus R0 is defined as the av-
erage number of newly infected cells produced by a single infected cell at the beginning
of the infection.
It is a well known result that R0 = 1 is a dynamic threshold [20, 26]. In other
words, R0 can be used as a metric to determine whether or not an infectious disease
will spread through a population. In fact, if R0 > 1 the infection becomes established
and if R0 < 1 the virus will not spread [26, 20].
The system given by equations (1)-(5) has the basic reproductive number:
R0 =
sβk
daµ
A stability analysis of the model, as well as properties of the solutions such as
positivity, boundedness, non periodicity, and limiting behavior can be found in [29].
The system of equations (1)-(5) supports five equilibrium points or steady states. The
stability of these points is determined by conditions on the parameters of the system
[29]. These equilibria are considered as qualitative scenarios that can be observed in
a typical host.
21
The first equilibrium point, also called disease free equilibrium, is globally asymp-
totically stable if R0 < 1 [29]. This scenario represents the absence of virus and
immune responses. The equilibrium point is given by the expression:(
T
(1)
, I
(1)
, V
(1)
, Z
(1)
,W
(1)
)
=
(s
d
, 0, 0, 0, 0
)
Figure 3: A disease free equilibrium point is observed if R0 ≤ 1. Parameter values were
chosen as follows: s = 1.0× 105, d = 1.0× 10−1, β = 0, a = 1.0× 10−2, p = 1.0× 10−2, k =
0, µ = 1.0 × 10−2, q = 1.0 × 10−2, g = 0, c = 0, h = 1.0 × 10−2, b = 1.0 × 10−2. Initial
conditions: T (0) = 1.0× 104, I(0) = 2.0× 100, V (0) = 3.0× 100, Z(0) = 1.0× 100,W (0) =
1.5× 100. According to the values of the parameters, R0 = 0.
In Figure 3, parameters have been chosen properly to give an illustration of this
first scenario. The proliferation of uninfected cells reaches its equilibrium value at
s
d
while the other four populations converge to zero. In this numerical illustration T (t)
converges to
s
d
= 106.
22
Under the assumption that R0 > 1 and that there is not an immune response, the
system converges to the equilibrium point given by:
(
T
(2)
, I
(2)
, V
(2)
, Z
(2)
,W
(2)
)
=
(
s
d
1
R0
,
µ
k
d
β
(R0 − 1) , d
β
(R0 − 1) , 0, 0
)
This equilibrium is globally asymptotically stable [29, 26] if
gkb
µc
< h and
cβhs
a(dg + βh)
< b
Figure 4: An endemic equilibrium where there is not an immune response is observed.
Parameter values were chosen as follows: s = 1.0× 105; d = 1.0× 10−1, β = 2.0× 10−7, a =
5.0 × 10−1, p = 6.4 × 10−4, k = 1.0 × 102, µ = 5.0 × 100, q = 5 × 10−1, g = 0, c = 0, h =
1 × 10−2, b = 2 × 10−2. Initial conditions: T (0) = 1.0 × 105, I(0) = 1.0 × 102, V (0) =
1.0 × 103, Z(0) = 2.0 × 100,W (0) = 1.0 × 100. According to the values of the parameters,
R0 > 1.
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In Figure 4, parameters have been chosen properly to give an illustration of this
scenario. The proliferation of uninfected cells, the number of viruses, and infected
cells reach their equilibrium values while the immune responses converge to zero.
The first two scenarios are mentioned for completeness. However, the focus in
this thesis is on the three scenarios in which R0 > 1 and there are immune responses.
These three scenarios are the following: dominant CTL response, dominant antibody
response, and coexistence (both CTL and antibody response are activated).
2.1.1 Dominant CTL Response
The third equilibrium observed is called dominant CTL response. A strong pro-
liferation of CTLs combined with a weak antibody production leads to an eventual
extinction of this response.
This scenario is described by the following equilibrium:
(
T
(3)
, I
(3)
, V
(3)
, Z
(3)
,W
(3)
)
=
(
sµc
dµc+ βkb
,
b
c
,
kI
(3)
µ
,
βT
(3)
V
(3) − aI(3)
pI
(3)
, 0
)
Notice that here we have that T
(3)
=
sµc
dµc+ βkb
, I
(3)
=
b
c
, and V
(3)
=
kb
µc
.
This equilibrium is globally asymptotically stable [29, 26] if
gkb
µc
< h and
cβhs
a(dg + βh)
> b
In Figure 5, values of parameters were chosen to illustrate this scenario where the
infection has become established. Large values of the viral load and infected cells
were chosen for the initial conditions to indicate the case of a chronic infection. See
caption of Figure 5 for details on the values of parameters and initial conditions. The
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Figure 5: Numerical solutions for equations (1)-(5) for the dominant CTL response scenario
with R0 > 1 where the third equilibrium is stable. An endemic equilibrium is observed.
Parameter values were chosen as follows: s = 2.0× 105, d = 1.0× 10−1, β = 2.0× 10−7, a =
5.0× 10−1, p = 6.4× 10−4, k = 2.0× 101, µ = 8.0× 100, q = 5.0× 10−1, g = 1.0× 10−11, c =
3.0 × 10−7, h = 1.0 × 10−1, b = 5.0 × 10−2. Initial conditions: T (0) = 1.0 × 106, I(0) =
1.6× 105, V (0) = 4.1× 105, Z(0) = 7.1× 101,W (0) = 5.0× 100.
virus persists in the presence of a dominant CTL response leading system going to
an endemic equilibrium.
Because parameter c is the proliferation rate of CTLs, for larger values of this
parameter, damped oscillations will be observed at the beginning of the simulation.
Infection will not become totally extinct, but a considerable reduction of the viral
load and infected cells will be observed.
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2.1.2 Dominant Antibody Response
The fourth equilibrium that is observed is called dominant antibody response.
The proliferation rate of antibody is assumed to be much stronger than the natural
production rate of CTLs. For this reason, the antibody response develops and the
CTL response is unsuccessful.
This scenario is described by the following equilibrium:
(
T
(4)
, I
(4)
, V
(4)
, Z
(4)
,W
(4)
)
=
(
sg
dg + βh
,
βhs
a(dg + βh)
,
h
g
, 0,
kI
(4) − µV (4)
qV
(4)
)
Notice that here we have that T
(4)
=
sg
dg + βh
, I
(4)
=
βhs
a(dg + βh)
, and V
(4)
=
h
g
.
This equilibrium is globally asymptotically stable [29, 26] if
gkb
µc
> h and
cβhs
a(dg + βh)
< b
In Figure 6, parameters were chosen to give an illustration of this scenario. Large
values of the viral load and infected cells were chosen for the initial conditions to
indicate the case of a chronic infection. The virus persists in the presence of a domi-
nant antibody response leading to an endemic equilibrium. Damped oscillations are
observed at the beginning of the simulation indicating that the antibody response is
unsuccessful in reducing the viral load.
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Figure 6: Numerical solutions for equations (1)-(5) for the dominant antibody response
scenario with R0 > 1 where the fourth equilibrium is stable. An endemic equilibrium is
observed. Parameter values were chosen as follows: s = 1.0 × 105, d = 5.0 × 10−2, β =
8.0 × 10−7, a = 1.8, p = 6.4 × 10−4, k = 8.0 × 100, µ = 1.5 × 100, q = 5.0 × 10−4, g =
8.0 × 10−8, c = 6.0 × 10−6, h = 1.0 × 10−2, b = 1.0 × 10−1. Initial conditions: T (0) =
1.0× 106, I(0) = 1.0× 105, V (0) = 1.0× 105, Z(0) = 5.0× 100,W (0) = 1.0× 101.
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2.1.3 Coexistence
The fifth and last equilibrium that is observed is called coexistence because both
CTL and antibody responses are equally established. These two immune responses
compete against each other with the same objective: eradication of the infection.
This scenario is described by the following equilibrium:
(
T
(5)
, I
(5)
, V
(5)
, Z
(5)
,W
(5)
)
=
(
sg
dg + βh
,
b
c
,
h
g
,
βT
(5)
V
(5) − aI(5)
pI
(5)
,
kI
(5) − µV (5)
qV
(5)
)
Notice that here we have that T
(5)
=
sg
dg + βh
, I
(5)
=
b
c
, and V
(5)
=
h
g
. This
equilibrium is globally asymptotically stable [29, 26] if
gkb
µc
> h and
cβhs
a(dg + βh)
> b
In Figure 7, parameters are chosen so as illustrate this scenario were the infection
has become established. Large values of the viral load and infected cells were chosen
for the initial conditions to indicate the case of a chronic infection. Even though the
viral load was brought to lower levels in comparison to the two previous scenarios,
infection still persists in the presence of antibody and CTL responses. In other words,
V (t) and I(t) do not tend to zero as t grows.
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Figure 7: Numerical solutions for equations (1)-(5) for the coexistence scenario with R0 > 1
where fifth equilibrium is stable. An endemic equilibrium is observed. Parameter values
were chosen as follows: s = 2.0 × 105, d = 1.0 × 10−1, β = 4.0 × 10−5, a = 9.9 × 10−1, p =
6.4 × 10−4, k = 5.0 × 102, µ = 2.9 × 100, q = 2.0 × 100, g = 1.0 × 10−5, c = 4.4 × 10−7, h =
2.0×10−1, b = 4.0×10−2. With initial conditions: T (0) = 2.2×105, I(0) = 1.0×105, V (0) =
1.9× 104, Z(0) = 7.0× 102,W (0) = 7.0× 102.
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3 SENSITIVITY ANALYSIS PART I
3.1 Introduction
Consider the system of differential equations given by
dx
dt
= f(t,x(t,θ),θ) (6)
where x(t,θ) ∈ Rn denotes the state variable vector at time t and θ ∈ Rp is the
parameter vector. It is of our interest to determine which of these parameters are
more important in the behavior of a particular state variable.
Definition 3.1 We define φ(t) =
∂x(t)
∂θ
to be the sensitivity matrix of x(t). This
matrix measures the sensitivity of the solution of (6) with respect to changes in the
parameters θk for k = 1, · · · , p.
By the chain rule for several variables and by assuming smoothness we have that
d
dt
φ(t) =
d
dt
(
∂x
∂θ
)
=
∂
∂θ
(
dx
dt
)
=
∂
∂θ
(f(t,x(t),θ)) =
∂f
∂θ
+
∂f
∂x
· ∂x
∂θ
To compute the sensitivities of (6) we solve what is called the system of sensitivity
equations given by:
dx
dt
= f(t,x(t,θ),θ) (7)
d
dt
∂x
∂θ
=
∂f
∂θ
+
∂f
∂x
· ∂x
∂θ
(8)
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Traditional sensitivity analysis is the quantification of the effect that changes in
parameters have on model solutions. Assume x(t) is a state variable of the model
given in (6). We can now define the traditional sensitivity function for x(t) [1].
Definition 3.2 The traditional sensitivity function for the solution model x(t) with
respect to θk is defined by
∂x
∂θk
(t) where k = 1, · · · , p.
Because parameters can have different units and state variables can be of different
orders of magnitude, we define the relative sensitivities of the state variable x(t) with
respect to the parameter θk as the product
θk
x(t)
∂x(t)
∂θk
(9)
Once the system of sensitivity equations (7)-(8) is solved, we can determine how
a specific state variable changes with respect to a given parameter θk. For instance,
if
∂x
∂θk
= 0 then the parameter θk has no influence in the behavior of the variable
x(t). If
∂x
∂θk
> 0 then the parameter θk has a positive influence in the behavior of
x(t). That is, for lager values of θk, x(t) will increase. Similarly, if
∂x
∂θk
< 0 then the
parameter θk has a negative impact in the behavior of x(t). That is, for larger values
of θk, x(t) will decrease.
In order to illustrate this concept we will find the sensitivities for some basic
examples. In our first two examples there is no need to compute the sensitivity
equations since the solutions of the models can be found analytically by standard
methods.
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Example 1 Consider the exponential growth model given by the initial value prob-
lem
dx
dt
= rx (10)
x(0) = x0 (11)
We know this model has solution x(t) = x0e
rt.
Since this model has only one parameter, the traditional sensitivity and the relative
sensitivity are given respectively by:
∂x
∂r
= x0te
rt and
r
x(t)
∂x
∂r
= rt
Notice that
r
x(t)
∂x
∂r
> 0 if r > 0 and
r
x(t)
∂x
∂r
< 0 if r < 0
Figure 8 shows the relative sensitivities of the model. If r > 0, then
r
x(t)
∂x
∂r
is a
monotonically increasing and positive function. In other words, the state function x(t)
increases as r grows. Similarly, if r < 0 then
r
x(t)
∂x
∂r
is a monotonically decreasing
and negative function. Which implies that the solution x(t) decreases as r grows. In
Figure 9 we have a numerical solutions for the model given by equations (10)-(11)
taking different values of r. In this figure, we can see that for positive values of r, as
this parameter grows x(t) will grow as well. For negative values of r, as this parameter
grows, the state variable x(t) decays faster.
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Figure 8: Relative sensitivities for the model given in Example 1
Figure 9: Numerical solutions of Example 1 with positive and negative values of r
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Example 2 Consider the initial value problem:
dx
dt
= a− bx
x(0) = x0
The vector of parameters is θ = (a, b).
For this example, the solutions of the sensitivities can be computed analytically. In
fact:
x(t) =
a
b
+
(
x0 − a
b
)
e−bt
Then the traditional sensitivities are
∂x
∂a
=
1
b
(
1− e−bt)
∂x
∂b
= − a
b2
(
1− e−bt)+ (a
b
− x0
)
te−bt
The relative sensitivities are:
a
x(t)
∂x
∂a
and
b
x(t)
∂x
∂b
.
Notice that
lim
t→+∞
a
x
∂x
∂a
=
1
b2
> 0, and lim
t→+∞
b
x
∂x
∂b
= −a
2
b4
< 0
This is, the relative sensitivity of x(t) with respect to a is always positive, which
implies that the parameter a has a positive influence in the behavior of x(t). In other
words, for larger values of a the function x(t) will increase. Likewise, the relative
sensitivity of x(t) with respect to b is always negative, which implies that for larger
values of b the function x(t) will decrease. The numerical solutions of the sensitivities
are given in Figure 10 and an illustration of the behavior of x(t) with respect to the
parameters a and b is given in Figure 11.
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Figure 10: Relative Sensitivities for the initial value problem in Example 2. Parameters
and initial condition were chosen as follows: a = 1, b = 1, and x(0) = 0.1.
Figure 11: (A) Numerical solution for x(t) fixing a and letting b vary. (B) Numerical
solution for x(t) fixing b and letting a vary. If we fix the value of a and we increase
parameter b we can see how function x(t) will reach smaller values. On the other hand, by
fixing parameter b and letting a increase, x(t) will reach larger values.
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Example 3 Consider the SIR model:
ds
dt
= −βsi (12)
di
dt
= βsi− γi (13)
1 = s(0) + i(0) (14)
Unlike Examples 1 and 2, the sensitivities for this model have to be calculated nu-
merically because an analytic solution does not exist. The sensitivities are found by
solving the following system:
dx
dt
= f(t,x(t,θ),θ)
d
dt
∂x
∂θ
=
∂f
∂θ
+
∂f
∂t
· ∂x
∂θ
where θ = (β, γ) is the vector of parameters.
Figure 12 exhibits the numerical solution of the model given by equations (12)-
(14). The population represented by s(t) decays from its initial condition to attain
its non-zero equilibrium point. On the other hand, the population represented by i(t)
shows a bell shaped curve having a maximum point nearly at t = 6.5 and eventually
going extinct.
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Figure 12: Numerical Solutions for the SIR model. Parameters and initial conditions
were chosen as follows: β = 2, γ = 1, s(0) = 0.998, and i(0) = 0.0013.
According to Figure 13, the larger the values of γ the smaller the values i(t)
attains. Similarly, the larger the values of β, the larger the values of i(t). This
is totally intuitive since β is the rate of production of i(t) and γ is the clearance
rate. Nevertheless, Figure 14 tells us that this behavior is not always like that.
Even though at the beginning of the simulation the sensitivities of β are positive and
the sensitivities of γ are negative, the role of these parameters changes. For values
of t > 7.2, the sensitivity of β becomes negative and the sensitivity of γ becomes
positive for values of t > 9. This means that for t ∈ (7.2,∞), if we increase β then
i(t) will reach smaller values. Additionally, for t ∈ (9,∞), if we increase γ then i(t)
will attain larger values.
37
Figure 13: Numerical Solutions of i(t) fixing β and γ show the effect of increasing
one parameter at a time. Initial conditions were chosen as follows: s(0) = 0.998, and
i(0) = 0.0013. The parameter values are displayed in the legend of the figure.
Figure 14: Relative sensitivities for i(t) versus time t show how the role of the pa-
rameters β and γ eventually switches. Parameters and initial conditions were chosen
as follows: β = 2, γ = 1, s(0) = 0.998, and i(0) = 0.0013.
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We are interested in calculating the relative sensitivities to the model given in
equations (1)-(5). This model can be written as
dx
dt
= f(t,x(t),θ) (15)
where x(t) = [T (t), I(t), V (t), Z(t),W (t)] , θ = (s, d, β, a, p, k, µ, q, c, b, g, h) is the
vector of the twelve parameters of the system, and f(t,x(t),θ) is the right hand side
of the system of equations.
In particular, we are interested in distinguishing what parameters play an impor-
tant role in the increasing or decreasing behavior of the viral load V (t). In order to
find the sensitivity matrix φ(t) =
∂x
∂θ
, which is a 5 × 12 matrix, numerical solutions
of corresponding sensitivity equations were computed. The third row of this matrix
is given by
∂V (t)
∂θ
, the change in V (t) with respect the parameters θ. Each entry will
tell us information of how V (t) changes with respect to each parameter. We use the
same values of parameters and initial conditions that we used in Section 2 to find the
numerical solutions of the system of sensitivity equations (7)-(8) for each scenario:
dominant CTL response, dominant antibody response, and coexistence.
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3.2 Relative Sensitivities: Dominant CTL Response
Using the values of parameters and initial conditions used in Section 2.1.1, nu-
merical simulations of the relative sensitivities were computed for a transient and
long-term phases for the dominant CTL response scenario.
Figure 15: Numerical solutions of the relative sensitivities θk
V
∂V
∂θk
for the dominant
CTL response scenario in a transient phase from 0 to 20
Figure 15 exhibits the transient phase where the parameters with more impact in
the behavior of V (t) are k and µ. This is because the relative sensitivities,
k
V (t)
∂V (t)
∂k
and
µ
V (t)
∂V (t)
∂µ
, have the most positive and negative values, respectively. This is not
surprising since k is the rate of proliferation and µ is the rate of natural decay of the
viral load.
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As seen in Figure 15, other parameters such as, β, a, s, and d also play an important
role in the behavior of V (t). In fact, if parameters β and s increase during this time
window of [0, 20] we would expect that the viral load will reach larger values. On the
other hand, parameters a and d have a negative influence in the behavior of V (t).
This is, if the rates of natural decay of uninfected and infected cells increase over
this period of time, then the number of viruses decreases. Once again this makes
total sense because the virus depends on these cells to get reproduced. A summary of
the parameters with more influence in the behavior of the viral load in the transient
phase can be found in Table 1.
Table 1: Ranking of the most influential parameters for dominant CTL response
in the transient phase. Increasing parameters k, β, and s will increase V (t) during
this phase. Similarly, increasing the values of parameters µ, a, and d will produce a
reduction in the number of viruses.
Positive Negative
k µ
Parameter β a
s d
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In the long-term phase shown in Figure 16, the parameters k and µ still are the
most influential parameters because their sensitivities are again the most positive and
negative functions. However, now these parameters are also joined by c and b, the
proliferation and natural decay rates of the CTL, respectively. It was not surprising
that these two parameters eventually would be responsible for the behavior of V (t)
since we are in the dominant CTL response scenario. It is also important to notice
that parameters β, a, s, and d that were important in the transient phase eventually
will become irrelevant. A summary of the most important parameters in the behavior
of V (t) in the long-term phase is given in Table 2.
Figure 16: Numerical solutions of the relative sensitivities θk
V
∂V
∂θk
for the dominant
CTL response scenario in a long-term phase from 0 to 500
42
Table 2: Ranking of the most influential parameters for the dominant CTL response
in the long-term phase. Increasing parameters k and b will increase V (t) during this
phase. Similarly, increasing the values of parameters µ and c will produce a reduction
in the number of viruses.
Positive Negative
k µ
Parameter b c
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3.3 Relative Sensitivities: Dominant Antibody Response
Numerical simulations of the sensitivities for the dominant antibody response
scenario were computed using the same values of the parameters used in Section 2.1.2.
These numerical simulations were calculated in transient and long-term phases.
Figure 17: Numerical solutions of the relative sensitivities θk
V
∂V
∂θk
for the dominant
antibody response scenario in a transient phase from 0 to 40
For the transient phase with t ∈ [0, 40], which is shown in Figure 17, the pa-
rameters that are most influential in the behavior of the virus load are µ, k, s, a, and
β because their sensitivities reach the most positive and negative values among all
the other sensitivities. However, because of the presence of an oscillatory behavior
on these sensitivities there are periods of time where their influence is stronger. A
summary of the most influential parameters in the behavior of the viral load is shown
in Table 3.
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Table 3: Ranking of parameters that are most influential for dominant antibody
response in the transient phase. Increasing parameters k, s and β will increase V (t)
during this phase. Similarly, increasing the values of parameters µ and a will produce
a reduction in the number of viruses.
Positive Negative
k µ
Parameter s a
β
A most interesting behavior is found in the long-term phase shown in Fig 18.
The oscillations that were observed in the transient phase continued until t = 70.
After this point, the sensitivities of s and k are clearly the most positive functions
and the sensitivities of µ and a are the most negative functions. However, at t = 450
something even more interesting and counterintuitive happened: the role of these four
parameters switch and two new parameters that so far were almost irrelevant become
the most influential. These new parameters are g and h: the rates of proliferation
and natural decay of the antibody response, respectively. Finally, for values of t >
1400 only these two parameters are in charge in the behavior of V (t). The other
parameters s, k, µ, and a eventually become irrelevant. A summary of the most
influential parameters in the long-term phase is shown in Table 4.
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Figure 18: Relative sensitivities θk
V
∂V
∂θk
for the dominant antibody response scenario
in a long-term phase from 0 to 2000
Table 4: Ranking of parameters for the relative sensitivities in the dominant antibody
response scenario in a long-term phase. Increasing parameter h will increase V (t)
during this phase. Similarly, increasing the value of parameter g will produce a
reduction in the number of viruses.
Positive Negative
Parameter h g
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3.4 Relative Sensitivities: Coexistence
Numerical solutions of the sensitivities for the coexistence scenario were calculated
using the same values of the parameters taken in Section 2.1.3. These solutions were
computed for transient and long-term phases.
Figure 19: Numerical solutions of the relative sensitivities θk
V
∂V
∂θk
for the coexistence
scenario in a transient phase from 0 to 20
It is reasonable to think that, in this scenario, V (t) will be mostly affected by the
values of parameters k, µ, c, b, h, and g since these parameters are proliferation and
natural decay rates of virus, CTL, and antibodies, respectively. However, as shown
in Figure 19, at the beginning of the simulation, from t = 0 to t = 2, V (t) looks to be
affected by the values of parameters k and q. After this point, for a short period of
time with t ∈ (1.8, 5) the sensitivities of s and g are the most positive and the most
negative, respectively. However, a unexpected outcome was obtained, in the transient
phase for t > 5 and in the long-term phase, shown in Figure 20, the viral load V (t) is
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affected only by the parameters g and h. In other words, in the coexistence scenario
the behavior of the viral load is affected only by the levels of production and reduction
of antibodies. A summary of the most influential parameters in the transient phase
and in the long-term phase is shown in Tables 5 and 6, respectively.
Table 5: Ranking of the most influential parameters of V (t) for the coexistence sce-
nario in a transient phase. Increasing parameters h, s, and k will increase V (t) during
this phase. Similarly, increasing the value of parameters g and q will produce a
reduction in the number of viruses.
Positive Negative
h g
Parameter s q
k
Figure 20: Relative sensitivities θk
V
∂V
∂θk
for the coexistence scenario in a long-term
phase from 0 to 150
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Table 6: Ranking of the most influential parameters of V (t) for the coexistence sce-
nario in a long-term phase. Increasing parameter h will increase V (t) during this
phase. Similarly, increasing the value of parameter g will produce a reduction in the
number of viruses.
Positive Negative
Parameter h g
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4 TREATMENT AS AN OPTIMAL CONTROL PROBLEM
4.1 Introduction
For several years antivirals such as interferon (IFN), pegylated-interferon (PEG-
INF) and ribavirin (RVB) have been used to reduce the levels of HCV RNA. In fact,
in approximately 50% of HCV treated patients with combinations of PEG-INF/RVB,
the virus is not eradicated [6, 14]. More recently treatments are focused on direct-
acting antiviral agents (DAAs) that target specific steps of the HCV life cycle [24].
Nevertheless, the use of these treatments is always restricted by their side effects.
In this section, we want to determine a best treatment strategy of a combination
of two antiviral medicines that reduces the infection and that minimizes the “cost”
effect to the body. We want to determine optimal treatment schedules for each of the
three scenarios discussed in the previous chapters.
The idea is to extend the system given by equations (1)− (5), with two piecewise
continuous functions u1(t) and u2(t) that describe a treatment strategy of a combina-
tion of two drugs over a certain fixed time horizon [0, tf ]. A best treatment strategy
has not only to consider the time where the medicines have to be administered but
also the side effects of the treatment to the human body. To approach the problem of
determining a best treatment strategy, we solve an optimal control problem. In this
thesis we provide definitions and concepts to our particular control problems. The
interested reader can find more general details in optimal control theory applied to
biological models in [18].
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Consider the extension of the equations (1)-(5) given by the system of differential
equations
dT
dt
= s− dT − (1− u1)βV T (16)
dI
dt
= (1− u1)βV T − aI − pIZ (17)
dV
dt
= (1− u2)kI − µV − qV W (18)
dZ
dt
= cIZ − bZ (19)
dW
dt
= gV W − hW (20)
where ui(t) = 1 represents maximal use of therapy and ui(t) = 0 corresponds to
minimal use of therapy, for i = 1, 2.
We rewrite the system of equations (16)− (20) as
dx
dt
= f(t,x(t), u1(t), u2(t)) (21)
where
x(t) = [T (t), I(t), V (t), Z(t),W (t)]
We define the set of admissible controls by
U = {(u1, u2) | u1, u2 measurable, 0 ≤ u1 ≤ 1, 0 ≤ u2 ≤ 1, t ∈ [0, tf ]} .
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In this context, an optimal controls problem consists on finding piecewise continu-
ous functions u1(t) and u2(t), called control functions in U , and the associated states
variables x(t) that minimize a given objective functional of the form
J(u1(t), u2(t)) =
∫ tf
0
G(t,x(t), u1(t), u2(t))dt
In other words, we are interested in solving the optimal control problem
min
u1,u2∈U
∫ tf
0
G(t,x(t), u1(t), u2(t))dt
subject to
dx
dt
= f(t,x(t), u1(t), u2(t))
x(t0) = x0
The main technique for such optimal control problems consists of solving a set of
necessary conditions that an optimal control pair and corresponding state variables
must satisfy. The necessary conditions we derive were developed by Pontryagin et al.
[22].
Before giving the necessary conditions we need to give the following definition:
Definition 4.1 The Hamiltonian H is defined by
H(t,x(t), u1(t), u2(t)) = G(t,x(t), u1(t), u2(t)) + λ(t) · f(t,x(t), u1(t), u2(t))
where λ(t) = [λ1(t), · · · , λ5(t)] is a piecewise differentiable vector-valued function,
and each λi is called the adjoint variable corresponding to xi.
We propose three different control problems to determine an optimal treatment for
each scenario: dominant CTL response, dominant antibody response and coexistence.
52
In other words, we define three different objective functionals for each scenario. To
find the solution to each problem we need to solve a set of necessary conditions, that
in general, are given in the next subsection but that will be studied in detail for each
scenario.
4.2 Necessary Conditions
The following theorem is an extension of Pontryagin’s Maximum Principle (Pon-
tryagin et al. [22]) given in Lenhart and Workman [18].
Theorem 4.2 Given the optimal control pair (u∗1(t), u
∗
2(t)) and solutions x
∗(t) of the
state system given by equations (16)-(20), there exists λ(t), a piecewise differentiable
vector-valued function, satisfying
H(t,x∗, u1(t), u2(t),λ(t)) ≥ H(t,x∗, u∗1(t), u∗2(t),λ(t))
for all u1(t), u2(t) ∈ U at each time t, where
dλj(t)
dt
= −∂H
xj
(Adjoint Equations)
and λj(tf ) = 0 for j = 1, · · · , 5 usually called the transversality conditions. The
optimality conditions are given by
0 =
∂H
∂uk
at u∗k for k = 1, 2 (Optimality Condition)
To solve the set of necessary conditions given in Theorem 4.2 we applied a forward-
backward sweep method. A much more detailed version of this method can be found
in [18].
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4.3 Forward-Backward Sweep Method
The optimality system given in Theorem 4.2 is solved numerically using a forward-
backward sweep method [18]. The following is an outline of the algorithm:
1. Make an initial guess for u over the interval.
2. Using the initial condition x = x(t0), and the values for u, solve x forward in
time according to its differential equation in the optimality system.
3. Using the transversality condition and the values for u and x, solve λ backward
in time according to its differential equation in the optimality system.
4. Update u by entering the new x and λ values into the characterization of the
optimal control.
5. Check for convergence. If values of the variables in this iteration and the last
iteration are negligibly close, output the current values as solutions. If values
are not close, return to step 2.
To the best of our knowledge, Chakrabarty and Joshi [4] were the first ones in
approaching the problem of finding an optimal combination treatment strategy using
optimal control theory. However, in their model they did not consider immune re-
sponses. Similar problems for optimizing chemotherapy in HIV models can be found
in [15, 4, 17]. Our aim is to determine an optimal treatment strategy for the three
scenarios seen in Section 2: dominant CTL response, dominant antibody response,
and coexistence.
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4.4 Optimal Treatment Strategy for the Dominant CTL Response Scenario
Under the assumption that the CTL response is much stronger than the antibody
response, we seek to minimize the number of infected cells I(t) and the “cost” based
on the effect of the treatment to the human body. For this reason, the objective
functional to be minimized is
J(u1, u2) =
∫ tf
0
(
A1I(t) +
1
2
(
A2u
2
1(t) + A3u
2
2(t)
))
dt
subject to the system
dT
dt
= s− dT − (1− u1)βV T
dI
dt
= (1− u1)βV T − aI − pIZ
dV
dt
= (1− u2)kI − µV − qV W
dZ
dt
= cIZ − bZ
dW
dt
= gV W − hW
The positive parameters A1, A2, and A3 balance the size terms. With higher
cost parameters A2 and A3, the system has controls where maximum treatment is
continued for a shorter period of time. In other words, with large values of these
parameters the cost effect of treatment is virtually not important. The severity of
therapy in the human body is described by the terms u21 and u
2
2. The reason behind
considering a finite time window is that the administration of treatment is usually
restricted to a limited time period.
Necessary conditions are derived by using the extension of Potryagin’s Maximum
Principle [22] given in Theorem 4.2.
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Theorem 4.3 Given the optimal control pair (u∗1(t), u
∗
2(t)) and solutions T
∗, I∗, V ∗, Z∗,W ∗
of the state system, there exists adjoint variables λ1, λ2, λ3, λ4, λ5 satisfying:
λ′1 = λ1 (d+ (1− u1)βV )− λ2(1− u1)βV
λ′2 = −A1 + λ2(a+ pZ)− λ3k(1− u2)− λ4cZ
λ′3 = λ1(1− u1)βT − λ2(1− u1)βT + λ3(µ+ qW )− λ5gW
λ′4 = λ2pI + λ4(b− cI)
λ′5 = λ3qV + λ5(h− gV )
with λ1(tf ) = λ2(tf ) = λ3(tf ) = λ4(tf ) = λ5(tf ) = 0, which are the transversality
conditions. Furthermore, the controls are characterized by
u∗1 = min
{
1,max
{
0,
(λ2 − λ1)βV ∗T ∗
A2
}}
u∗2 = min
{
1,max
{
0,
λ3kI
∗
A3
}}
Proof:
The Hamiltonian is defined as follows:
H(t,x(t), u1(t), u2(t),λ(t)) = A1I +
1
2
(
A2u
2
1(t) + A3u
2
2(t)
)
+λ1(s− dT − (1− u1(t))βV T )
+λ2((1− u1(t))βV T − aI − pIZ)
+λ3((1− u2(t))kI − µV − VW )
+λ4(cIZ − bZ)
+λ5(gV W − hW )
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We obtain the adjoint equations:
λ′1 = −
∂H
∂T
= λ1 (d+ (1− u1)βV )− λ2(1− u1)βV
λ′2 = −
∂H
∂I
= −A1 + λ2(a+ pZ)− λ3k(1− u2)− λ4cZ
λ′3 = −
∂H
∂V
= λ1(1− u1)βT − λ2(1− u1)βT + λ3(µ+ qW )− λ5gW
λ′4 = −
∂H
∂Z
= λ2pI + λ4(b− cI)
λ′5 = −
∂H
∂W
= λ3qV + λ5(h− gV )
with λ1(tf ) = λ2(tf ) = λ3(tf ) = λ4(tf ) = λ5(tf ) = 0. In order to obtain the optimality
condition, we maximize the Hamiltonian with respect to u1 and u2 at the optimal u
∗
1
and u∗2, respectively.
This is,
∂H
∂ui
= 0 at u∗i for i = 1, 2.
Therefore,
u∗1 =
(λ2 − λ1)βV ∗T ∗
A2
and u∗2 =
λ3kI∗
A3
By standard routines of optimal control problems with bounded controls [4, 9, 15, 17,
18] the characterizations of the optimal controls are given by:
u∗1 = min
{
1,max
{
0,
(λ2 − λ1)βV ∗T ∗
A2
}}
u∗2 = min
{
1,max
{
0,
λ3kI
∗
A3
}}

The forward-backward-sweep method was used to find the numerical solutions of
the optimal control problem in the time window [0, tf ] with tf = 50. These solutions
are given in Figure 21.
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Figure 21: Numerical solutions and best treatment strategies. (A) shows the numer-
ical solutions of the system with no treatment. (B) shows the effect of one session of
treatment.(C) and (D) show the best treatment strategy. Parameters were chosen as
follows: s = 2.0×105, d = 1.0×10−1, β = 2.0×10−7, a = 5.0×10−1, p = 6.4×10−4, k =
2.0 × 101, µ = 8.0 × 100, q = 5.0 × 10−1, g = 1.0 × 10−11, c = 3.0 × 10−7, h = 1.0 ×
101−, b = 5.0× 10−2, A1 = 1.0× 100, A2 = 5.0× 10−3, A3 = 1.0× 10−2, tf = 5.0× 101.
Initial conditions: T (0) = 1.0 × 106, I(0) = 1.6 × 105, V (0) = 4.1 × 105, Z(0) =
7.1× 101,W (0) = 5.0× 100.
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Figure 21 (C) and (D) exhibits the controls u∗1 and u
∗
2, that are the optimal
treatment routines suggested by the model. According to the numerical solutions, the
drug that suppresses the production of infected cells, i.e. u1, must be administered
in full scale from t = 0 to t = 2. Then, u∗1 is tapered off from t = 2 to t = 16. Finally,
u∗1 has to be administered in full scale again, this time from t = 16 to t = 35. On
the other hand, the model suggests that the drug that interferes in the production of
virus, u∗2, must be administered in full scale from t = 0 to t = 15. Then, the dose is
tapered off from t = 15 to t = 35 and administered again in a much lower scale for
35 < t < 50.
Figure 21 (A) shows the numerical solutions of the model given by equations (16)-
(20) assuming no treatment has been administered. In other words, u1(t) = 0 and
u2(t) = 0. The value of the parameters and initial conditions are the same that were
used in Section 2.1.1.
In Figure 21 (B) we have the numerical solutions of the optimal control problem
for the state variables. This solution shows how the viral load and number of infected
cells are affected by the effect of treatment. With the treatment schedule suggested
by the model, we see a sharp decrease in the log of the viral load describing a biphasic
decline followed by a rebound at the moment treatment u2 is tapered off. However,
this rebound is controlled by the drug u1 that keeps the viral load at low levels.
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To understand what happens after cessation of therapy, we solved the optimal
control problem in two parts: first, we let u1 and u2 to be non zero functions from
t = 0 to 50 to compute the forward-backward method in this time window. Second,
we let u1 = 0 and u2 = 0 from t = 50 to t = 150 and calculated the numerical
solutions. These numerical solutions are shown in Figure 22.
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Figure 22: Numerical solutions after cessation of therapy. A continuation of the first
treatment schedule was computed. We let u2 and u2 to be activated in the time
window [0, 50]. Then we let u1 = 0 and u2 = 0 for t ∈ [50, 150]. (A) numerical
solutions of the system with no treatment; (B) levels of virus rebound after cessation
of treatment for t > 50; (C) and (D) are the continuation of the best treatment
schedules.
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It is reasonable to ask, what is the benefit of therapy if after treatment the vi-
ral load rebounds to its pretreatment levels? To provide a plausible answer to this
question, we calculate the number of new viruses produced and the number of new
infected cells produced during treatment and with no treatment. The rate of produc-
tion of new viruses is given by the term kI, where k has units of
1
time
, then kI has
units of
cells
time
.
Therefore, if the patient is not under treatment,∫ tf
0
kI dt
is an approximation of the total production of infected cells over the interval [0, tf ].
Similarly, during therapy ∫ tf
0
(1− u2)kI dt
is the total production of virus over the interval [0, tf ].
Table 7 shows the comparison of the total production of virus during treatment
and with no treatment. During treatment the production of new virus decreases
in five orders of magnitude. However, after cessation of treatment and running the
simulation until t = 150, the number of viruses is of the same order of magnitude.
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Table 7: The total production of virus was computed to compare the dominant CTL
response scenario under treatment and with no treatment
No Treatment Treatment
Total production
∫ 50
0
kI dt = 1.58× 108
∫ 50
0
(1− u2)kI dt = 1.43× 103
of new virus
∫ 150
0
kI dt = 4.96× 108
∫ 150
0
(1− u2)kI dt = 2.66× 108
Table 8: The total production of infected cells was computed to compare the
dominant CTL response scenario under treatment and with no treatment
No Treatment Treatment
Total production
∫ 50
0
βV Tdt = 4.27× 106
∫ 50
0
(1− u1)βV Tdt = 1.21× 10−2
of infected cells
∫ 150
0
βV Tdt = 1.31× 107
∫ 150
0
(1− u1)βV Tdt = 6.87× 106
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The production of new virus is assumed to be the number of interactions between
free virus particles and uninfected cell. Therefore, the total production of new infected
cells before treatment is given by the integral∫ tf
0
βV T dt.
Similarly, the total production of new infected cells during treatment is calculated by∫ tf
0
(1− u1)βV T dt.
Table 8 shows the comparison of these two quantities. During treatment for t ∈
[0, 50] the production of new virus decreases in eight orders of magnitude. However,
after cessation of therapy and computing the numerical solutions for t ∈ [0, 150] the
production of new infected cells is reduced only in one order of magnitude.
According to Tables 7 and 8, the benefit of therapy is precisely during the period of
time the drug is being administered. If the goal of therapy is to reduce the levels of
the viral load to undetectable numbers in a certain fixed time horizon, the optimal
schedule suggested here is the desired treatment routine.
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Figure 23: Comparison of the viral load under treatment and without treatment in a
non logarithmic scale for the dominant CTL response scenario. The viral load with
a non logarithmic scale during treatment (red curve) and with no treatment (blue
curve) show that on the short term, the viral load decays significantly. However, on
the long-term the steady state level is higher than without treatment. Worst than
leaving untreated.
Figure 23 shows the numerical solution of V (t) in a non logarithmic scale during
treatment (red curve) and with no treatment (blue curve). During the administration
of drugs, the viral load is maintained in considerably lower levels. This reduction in
the number of viruses continues even after cessation of therapy. However, eventually
V (t) rebounds to levels that are higher than without treatment. This is the reason
why in Table 7 the number of viruses is of the same order of magnitude during
treatment than with no treatment in the long-term.
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4.5 Optimal Treatment Strategy for the Dominant Antibody Response Scenario
As stated in Section 2, in this scenario we assume a vigorous antibody response
combined with a weak CTL response. Because the antibodies play the role of neu-
tralizing the production of new virus, we seek to minimize the function V (t) and the
“cost” based on the effect of the therapy to the body. The objective functional to be
minimized is
J(u1, u2) =
∫ tf
0
(
A1V (t) +
1
2
(
A2u
2
1(t) + A3u
2
2(t)
))
dt
subject to the system
dT
dt
= s− dT − (1− u1)βV T
dI
dt
= (1− u1)βV T − aI − pIZ
dV
dt
= (1− u2)kI − µV − qV W
dZ
dt
= cIZ − bZ
dW
dt
= gV W − hW
The parameters A1, A2, and A3 balance the size terms. With higher cost param-
eters A2 and A3, the system has controls where maximum treatment is continued for
a shorter period of time. In other words, with large values of these parameters the
cost effect of treatment is virtually not important. The severity of therapy in the
human body is described by the terms u21 and u
2
2. The reason for considering a finite
time window is that the administration of treatment is usually restricted to a limited
time period. Necessary conditions are derived by using the extension of Pontryagin’s
Maximum Principle [22] given in Theorem 4.2.
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Theorem 4.4 Given the optimal control pair (u∗1(t), u
∗
2(t)) and solutions T
∗, I∗, V ∗, Z∗,W ∗
of the state system, there exists adjoint variables λ1, λ2, λ3, λ4, λ5 satisfying:
λ′1 = λ1 (d+ (1− u1)βV )− λ2(1− u1)βV
λ′2 = λ2(a+ pZ)− λ3k(1− u2)− λ4cZ
λ′3 = −A1 + λ1(1− u1)βT − λ2(1− u1)βT + λ3(µ+ qW )− λ5gW
λ′4 = λ2pI + λ4(b− cI)
λ′5 = λ3qV + λ5(h− gV )
with λ1(tf ) = λ2(tf ) = λ3(tf ) = λ4(tf ) = λ5(tf ) = 0, which are the transversality
conditions. Furthermore, the characterization of the control is given by
u∗1 = min
{
1,max
{
0,
(λ2 − λ1)βV ∗T ∗
A2
}}
u∗2 = min
{
1,max
{
0,
λ3kI
∗
A3
}}
Proof:
The Hamiltonian is defined as follows:
H(t,x(t), u1(t), u2(t),λ(t)) = A1V +
1
2
(
A2u
2
1(t) + A3u
2
2(t)
)
+λ1(s− dT − (1− u1(t))βV T )
+λ2((1− u1(t))βV T − aI − pIZ)
+λ3((1− u2(t))kI − µV − VW )
+λ4(cIZ − bZ)
+λ5(gV W − hW )
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We obtain the adjoint equations:
λ′1 = −
∂H
∂T
= λ1 (d+ (1− u1)βV )− λ2(1− u1)βV
λ′2 = −
∂H
∂I
= λ2(a+ pZ)− λ3k(1− u2)− λ4cZ
λ′3 = −
∂H
∂V
= −A1 + λ1(1− u1)βT − λ2(1− u1)βT + λ3(µ+ qW )− λ5gW
λ′4 = −
∂H
∂Z
= λ2pI + λ4(b− cI)
λ′5 = −
∂H
∂W
= λ3qV + λ5(h− gV )
with λ1(tf ) = λ2(tf ) = λ3(tf ) = λ4(tf ) = λ5(tf ) = 0. In order to obtain the optimality
condition, we maximize the Hamiltonian with respect to u1 and u2 at the optimal u
∗
1
and u∗2, respectively.
This is,
∂H
∂ui
= 0 at u∗i for i = 1, 2.
Therefore,
u∗1 =
(λ2 − λ1)βV ∗T ∗
A2
and u∗2 =
λ3kI∗
A3
By standard routines of optimal control problems with bounded controls [4, 9, 15, 17,
18] the characterizations of the optimal controls are given by:
u∗1 = min
{
1,max
{
0,
(λ2 − λ1)βV ∗T ∗
A2
}}
u∗2 = min
{
1,max
{
0,
λ3kI
∗
A3
}}

The forward-backward-sweep method was used to find the numerical solutions of
the optimal control problem in the time window [0, tf ] with tf = 40. These numerical
solutions are shown in Figure 24.
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Figure 24: Numerical solutions and best treatment strategies. (A) shows the numer-
ical solutions of the system with no treatment. (B) shows the numerical solutions
of the system with treatment. (C) and (D) describe the best treatment strategies.
Parameter were chosen as follows: s = 1 × 105, d = 5 × 10−2, β = 8 × 10−7, a =
1.8, p = 6.4 × 10−4, k = 8, µ = 1.5, q = 5 × 10−4, g = 8 × 10−8, c = 6 × 10−6, h =
0.01, b = 0.1, A1 = 001, A2 = 50, A3 = 3500, tf = 40.
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In Figure 24 (C) and (D), the controls u∗1 and u
∗
2 represent the drug administration
schedule. The model suggests that u∗1 must be administered in full scale from t = 9
to t = 15, then it must be reduced to much lower levels and turned off from t = 26
to t = 36. Finally, it has to be administered again for a short period of time from
t = 36 to t = 38 and eventually tapered off again. On the other hand, u∗2 must start
being fully administered from t = 8 to t = 14, it is turned off until t = 26 and finally
for values from t = 26 to t = 40, this drug must be administered in levels no larger
than 40% of the total dosage.
We computed a continuation of the numerical solutions letting the controls being
activated from t = 0 to t = 40 and then letting them be zero from t = 40 to t = 150.
In Figure 25 (B), we can see how after cessation of treatment the viral load and
infected cells rebound to their pretreatment levels.
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Figure 25: Numerical solutions after cessation of therapy. A continuation of the first
treatment schedule was computed. We let u1 and u2 to be activated in the time win-
dow [0, 40]. Then we let u1 = 0 and u2 = 0 for t ∈ [40, 150]. (A) numerical solutions
of the system with no treatment; (B) levels of virus and infected cells rebound after
cessation of therapy at t = 40; (C) and (D) are the best treatment schedules.
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It is clear that the effect of the therapy in this scenario is not as promising as in
the CTL dominance scenario. In fact, in Table 9 we can notice that with this treat-
ment schedule the production of new virus does not decrease in orders of magnitude.
However, a reduction of one order of magnitude in the number of newly infected cells
can be observed in Table 10.
Table 9: The total production of virus was computed to compare the dominant
antibody response scenario under treatment and with no treatment
No Treatment Treatment
Total production
∫ 40
0
kI dt = 1.67× 107
∫ 40
0
(1− u2)kI dt = 1.24× 107
of new virus
∫ 150
0
kI dt = 5.52× 107
∫ 150
0
(1− u2)kI dt = 5.12× 107
Table 10: The total production of infected cells was computed to compare the
dominant antibody response scenario under treatment and with no treatment
No Treatment Treatment
Total production
∫ 40
0
βV Tdt = 3.72× 106
∫ 40
0
(1− u1)βV Tdt = 3.00× 106
of infected cells
∫ 150
0
βV Tdt = 1.23× 107
∫ 150
0
(1− u1)βV Tdt = 1.17× 107
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Figure 26 shows the comparison of the viral load with treatment and with no
treatment for the dominant antibody response scenario. The rebound of V (t) during
treatment explains why the production of new viruses, shown in Table 9, does not
decrease drastically as in the dominant CTL scenario. In the long-term it is neither
worse nor better, because steady state levels are the same.
Figure 26: Comparison of the viral load under treatment and without treatment in
a non logarithmic scale for the dominant antibody response scenario. The viral load
with a non logarithmic scale during treatment (red curve) and with no treatment (blue
curve) show that on the short term, the viral load oscillates about the equilibrium
point. In the long-term, the values of the viral load during treatment and with no
treatment stay at the equilibrium point.
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4.6 Optimal Treatment Strategy for the Coexistence Scenario
Under the assumption that both CTL and antibody responses develop, we want
to minimize the number of viruses V (t), the number of infected cells I(t), and the
“cost” based on the effect of the therapy to the body. For this reason, the objective
functional to be minimized is
J(u1, u2) =
∫ tf
0
(
A1I(t) + A2V (t) +
1
2
(
A3u
2
1(t) + A4u
2
2(t)
))
dt
subject to the system
dT
dt
= s− dT − (1− u1)βV T
dI
dt
= (1− u1)βV T − aI − pIZ
dV
dt
= (1− u2)kI − µV − qV W
dZ
dt
= cIZ − bZ
dW
dt
= gV W − hW
The parameters A1, A2, and A3 balance the size terms. With higher cost param-
eters A2 and A3, the system has controls where maximum treatment is continued for
a shorter period of time. In other words, with large values of these parameters the
cost effect of treatment is virtually not important. The severity of therapy in the
human body is described by the terms u21 and u
2
2. The reason for considering a finite
time window is that the administration of treatment is usually restricted to a limited
time period. Necessary conditions are derived by using the extension of Pontryagin’s
Maximum Principle [22] given in Theorem 4.2.
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Theorem 4.5 Given the optimal control pair (u∗1(t), u
∗
2(t)) and solutions T
∗, I∗, V ∗, Z∗,W ∗
of the state system, there exists adjoint variables λ1, λ2, λ3, λ4, λ5 satisfying:
λ′1 = λ1 (d+ (1− u1)βV )− λ2(1− u1)βV
λ′2 = −A1 + λ2(a+ pZ)− λ3k(1− u2)− λ4cZ
λ′3 = −A2 + λ1(1− u1)βT − λ2(1− u1)βT + λ3(µ+ qW )− λ5gW
λ′4 = λ2pI + λ4(b− cI)
λ′5 = λ3qV + λ5(h− gV )
with λ1(tf ) = λ2(tf ) = λ3(tf ) = λ4(tf ) = λ5(tf ) = 0, which are the transversality
conditions. Furthermore, the optimal controls are characterized by
u∗1 = min
{
1,max
{
0,
(λ2 − λ1)βV ∗T ∗
A3
}}
u∗2 = min
{
1,max
{
0,
λ3kI
∗
A4
}}
Proof:
The Hamiltonian is defined as follows:
H(t,x(t), u1(t), u2(t),λ(t)) = A1I + A2V +
1
2
(
A3u
2
1(t) + A4u
2
2(t)
)
+λ1(s− dT − (1− u1(t))βV T )
+λ2((1− u1(t))βV T − aI − pIZ)
+λ3((1− u2(t))kI − µV − VW )
+λ4(cIZ − bZ)
+λ5(gV W − hW )
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We obtain the adjoint equations:
λ′1 = −
∂H
∂T
= λ1 (d+ (1− u1)βV )− λ2(1− u1)βV
λ′2 = −
∂H
∂I
= −A1 + λ2(a+ pZ)− λ3k(1− u2)− λ4cZ
λ′3 = −
∂H
∂V
= −A2 + λ1(1− u1)βT − λ2(1− u1)βT + λ3(µ+ qW )− λ5gW
λ′4 = −
∂H
∂Z
= λ2pI + λ4(b− cI)
λ′5 = −
∂H
∂W
= λ3qV + λ5(h− gV )
with λ1(tf ) = λ2(tf ) = λ3(tf ) = λ4(tf ) = λ5(tf ) = 0. In order to obtain the optimality
condition, we maximize the Hamiltonian with respect to u1 and u2 at the optimal u
∗
1
and u∗2, respectively.
This is,
∂H
∂ui
= 0 at u∗i for i = 1, 2.
Therefore,
u∗1 =
(λ2 − λ1)βV ∗T ∗
A3
and u∗2 =
λ3kI∗
A4
By standard routines of optimal control problems with bounded controls [4, 9, 15, 17,
18] the characterizations of the optimal controls are given by:
u∗1 = min
{
1,max
{
0,
(λ2 − λ1)βV ∗T ∗
A2
}}
u∗2 = min
{
1,max
{
0,
λ3kI
∗
A3
}}

The forward-backward-sweep method was used to find the numerical solutions of
the optimal control problem in the time window [0, tf ] with tf = 15. These numerical
solutions are shown in Figure 27.
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Figure 27: Numerical solutions and best treatment strategies. (A) shows the numer-
ical solutions of the system with no treatment. (B) shows the numerical solutions
of the system with treatment. (C) and (D) describe the best treatment strategies.
Parameters were chosen as follows: s = 2.0× 105, d = 1.0× 10−1, β = 4.0× 10−5, a =
9.9×10−1, p = 6.4×10−4, k = 5.0×102, µ = 2.9×100, q = 2.0×100, g = 1.0×10−5, c =
4.4 × 10−7, h = 2.0 × 10−1, b = 4.0 × 10−2, A1 = 1.0 × 100, A2 = 1.0 × 100, A3 =
4.0 × 104, A4 = 4.7 × 104, tf = 1.5 × 101. The large values taken for the parameters
A3 and A4 indicate the cost of the therapy on the human body. In other words, the
side effects of the therapy are assumed to be substantial.
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Figure 27 (A) shows the numerical solutions of the model with no treatment.
The parameter values and initial conditions used in this calculations were the same
used in Section 2.1.3. Figure 27 (C) and (D) represent the drug administration
schedule. The model suggests that drug represented by the control function u∗2 must
be administered in full scale from t = 2 to t = 7. After this point, this drug is
tapered off and fully administered again from t = 12.7 to t = 14.3. This regime will
drop the number of viruses by about 10 orders of magnitude. On the other hand, the
treatment represented by the control u∗1 is hardly used and it has to be administered
just for a short period of time at t = 14. For this reason, the level of infected cells
does not decrease as much as the viral load. In Figure 27 (B), we have displayed the
numerical solutions of the optimal control problem during a time horizon from t = 0
to t = 15. These solutions show the outcomes of applying the suggested treatment
schedule. After cessation of treatment, the viral load and the number of infected
cells return to their pretreatment levels. This is illustrated in Figure 28 (B), which
shows the continuation of the numerical solutions of the optimal control problem after
cessation of therapy.
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Figure 28: Numerical solutions after cessation of therapy. A continuation of the first
treatment schedule was computed. We let u1 and u2 to be activated in the time
window [0, 15]. Then we let u1 = 0 and u2 = 0 for t ∈ [15, 30]. (A) shows the
numerical solutions of the system with no treatment. (B) shows how the levels of
virus and infected cells rebound after cessation of therapy at t = 15. (C) and (D)
describe the best treatment strategies.
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Tables 11 and 12 show that there is not a significant reduction in the number
of newly formed viruses and infected cells during treatment. In fact, these numbers
do not change in orders of magnitude regardless of the administration of treatment.
In order to understand such a contradicting result, we refer the reader to Figure
29, that shows the viral load in a non logarithmic scale during treatment and with
no treatment. From this figure, it is clear that even though the number of viruses
was reduced during therapy, when the treatment is tapered off, V (t) rebounds to its
pretreatment levels through damp oscillations. In some of these oscillations, the viral
load reaches numbers much larger than in the non treatment scenario. Again, the
benefit of therapy is just observed during short periods of time.
Table 11: The total production of virus in a non logarithmic scale was computed to
compare the coexistence scenario under treatment and with no treatment
No Treatment Treatment
Total production
∫ 15
0
kI dt = 8.40× 108
∫ 15
0
(1− u2)kI dt = 5.86× 108
of new virus
∫ 30
0
kI dt = 1.70× 109
∫ 30
0
(1− u2)kI dt = 1.55× 109
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Table 12: The total production of infected cells was computed to compare the
coexistence scenario under treatment and with no treatment
No Treatment Treatment
Total production
∫ 15
0
βV Tdt = 2.56× 106
∫ 15
0
(1− u1)βV Tdt = 1.90× 106
of infected cells
∫ 30
0
βV Tdt = 5.22× 106
∫ 30
0
(1− u1)βV Tdt = 4.92× 106
Figure 29: Comparison of the viral load under treatment and without treatment in
a non logarithmic scale for the coexistence scenario. The numerical solutions of the
viral load with a non logarithmic scale during treatment (red curve) and with no
treatment (blue curve) show that at t = 8, V (t) rebounds to large values. However,
this rebound is just for a short period of time. Eventually, V (t) decreases and in the
the long-term, the values of the viral load during treatment and with no treatment
stay at the equilibrium point.
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5 INVERSE PROBLEM: PARAMETER ESTIMATION
Experimental data sets exhibiting HCV RNA levels from chronic HCV patients
treated with several types of drugs can be found in existing literature [6, 12, 19].
With these data sets, one can estimate a set of parameters that gives the best fit of
the data with a model. This problem is called the inverse problem. We address this
problem using an ordinary least squares (OLS) method to find a first estimation of
the parameters and then with a bootstrap method to find a new set of parameter
estimates and their corresponding standard errors.
5.1 Ordinary Least Squares
The formulation of the standard ordinary least squares usually involves two mod-
els: a mathematical model and a statistical model [1]. Assume we have a problem
modeled by a system of differential equations of the form
dx
dt
= f(t,x(t,θ),θ)
where x(t,θ) ∈ Rn denotes the state variable vector at time t and θ ∈ Rp de-
notes the parameter vector. The output of the mathematical model is denoted by
z(ti,θ0). In this case, z(ti,θ0) is a functional of the state variable x(t,θ), that is,
z(ti,θ0) ∈ F (x(t,θ)) and θ0 is the true parameter vector. The statistical model for
the observation process is given by the random variables
Yi = z(ti,θ0) + Ei for i = 1, 2, · · · , n.
For example, in our model the statistical model for the observation process is
Yi = ln (V (ti,θ0)) + Ei
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The errors Ei are assumed to be random variables that satisfy [1]:
1. Ei for for i = 1, 2, · · · , n are independent and identically distributed random
variables. This is, cov(Ei,Ej) = 0 whenever i 6= j.
2. E [Ei] = 0 for every i.
3. var(Ei) = σ20 <∞, for every i.
We use the ordinary least squares method to minimize [Yi − ln (V (ti,θ))]2 over
the set of parameter vectors θ constrained by a pre-specified feasible region denoted
by Θ. The minimizer is a random variable, called the estimator θOLS given by
θOLS = argminθ∈Θ
n∑
i=1
[Yi − ln (V (ti,θ))]2
The theoretical quantities θ0 and σ
2
0 are in general unknown. In practice, one
has only the data associated with a single realization yi of the observation process Yi
for i = 1, · · · , n and has no option but to compute an estimate for θˆOLS. Using the
genetic algorithm in MATLAB we carry out the following minimization process:
θˆOLS = argminθ∈Θ
n∑
i=1
[yi − ln (V (ti,θ))]2
The reader can find more details and examples of using the OLS method for parameter
estimation in [1].
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5.2 The Bootstrap Method
The bootstrap method not only gives us parameter point-estimates but also an
interval of possible values or confidence intervals. The bootstrap method uses an
empirical distribution for the statistic based just on the data at hand. This empirical
distribution can be generated through resampling. Resampling takes random samples
with replacement(of the same size) from the original sample.
The following is the outline of the algorithm [2] :
1. Let θˆ
(0)
to be the vector of parameters estimates from the entire dataset {y1, y2, · · · , yn}
using OLS.
2. Using this estimate we define the standard residuals:
rj =
√
n
n− p
(
yj − ln
(
V (ti, θˆ
(0)
)
))
for j = 1, · · · , n. Then {r1, · · · , rn} are realizations of independent identically dis-
tribute (i.i.d) random variables Rj from an empirical distribution Fn.
3. Set m = 0 and create a bootstrap sample of size n using random sampling with
replacement from {r1, · · · , rn} to form a bootstrap sample
{
r
(m)
1 , · · · , r(m)n
}
.
4. Create bootstrap sample points (for j = 1, · · · , n)
y
(m)
j = ln
(
V (ti, θˆ
(0)
)
)
+ r
(m)
j
5. Obtain a new estimate θˆ
(m+1)
from the bootstrap sample
{
y
(m)
j
}
.
6. Set m = m+ 1 and repeat steps 3-5.
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We carried out the iterative process m = 10, 000 times. Once this process is
finished, we compute mean, covariance matrix, and standard errors using the following
formulas:
θˆboot =
1
M
M∑
m=1
θˆ
(m)
(22)
Cov
(
θˆboot
)
=
1
M − 1
M∑
m=1
(
θˆ
(m) − θˆboot
)(
θˆ
(m) − θˆboot
)T
(23)
SEk
(
θˆboot
)
=
√
Cov
(
θˆboot
)
kk
(24)
where
(
θˆboot
)
∈ Rp is assumed to be a column vector.
To evaluate the model, we fit data sets taken from existing literature [6, 7, 12, 19].
First of all, we find point estimates for the twelve parameters of the system using OLS.
Secondly, we run the bootstrap method to find new point estimates along with their
standard errors. However, the problem of finding the point estimates and intervals of
confidence for these parameters having only data sets of the viral load is a complex
problem due to the lack of information on the other variables that are involved. For
this reason, for some parameters we were able to find only point estimates; their
standard errors were not confident enough.
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Different HCV RNA profiles of patients under treatment have been observed,
namely: rebound to baseline values, biphasic decay, triphasic decay, and flat second
phases after cessation of therapy. The model given by equations (1)-(5) could be
fit to all of these profile observations with exception of the triphasic decay. The
consideration of a logistic term in the equations for the proliferation of hepatocytes
may yield to a more realistic model that can also be fit to a triphasic decay data
[6]. However, the inclusion of such a term would imply an increase in the number of
parameters. More details about the bootstrapping method can be found at [2].
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5.2.1 Parameter Estimation for Patient 1
The data set taken from Neumann et al. [19] was used to find point estimates of the
parameters. A MATLAB code was run to solve an OLS optimization problem using
the genetic algorithm. Initial conditions for the uninfected and infected cells were also
computed in the optimization process. With these first point estimates, a bootstrap
method was computed with 10,000 iterations to get a new set of parameter estimates
with their corresponding standard errors. Point estimates and their standard errors
are summarized in Table 13.
Table 13: Bootstrap estimates and standard errors for patient 1
Parameter Bootstrap Estimate Standard Error (SE)
s 8.7386× 103 t.l.n.r.
d 1.0700× 10−2 1.5000× 10−2
β 1.9677× 10−5 2.0170× 10−5
a 1.6010× 10−1 1.5090× 10−1
p 6.5859× 10−4 7.7706× 10−4
k 5.4780× 10−1 2.0880× 10−1
µ 2.8595× 100 4.6500× 10−1
q 9.5861× 10−4 t.l.n.r.
c 4.5438× 10−7 t.l.n.r.
b 1.8060× 10−1 t.l.n.r.
g 9.6712× 10−7 t.l.n.r.
h 6.2800× 10−1 9.7510× 10−1
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Table 13 shows the parameter estimates and standard errors found in the boot-
strapping. For some parameters, large standard errors were obtained. This is not
surprising due to the large variability that was observed for some data points in the
cloud provided in Figure 30. This large variability is due to the fact that the ob-
servations in the data points vary in several orders of magnitude. This explains the
fact that for the data points that were taken after day 5 we observe larger variability.
These issues reveal the limitations of the OLS method. The use of generalized ordi-
nary least squares (GOLS) [1] might be a possible solution to this weakness in our
method.
Figure 30: Bootstrap cloud for patient 1. Running the bootstrap algorithm for 10,000
iterations a cloud of best fit solutions is plotted. Parameter estimates and standard
errors are calculated after the iterative process.
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For those parameters with standard errors that are larger than the estimation,
only their point estimates are shown on Table 13. Instead we use the abbreviation
“t.l.n.r.”, which stands for “too large not reported”. In Figure 30, the best fits
found with the bootstrap and the data points were plotted. The thickness of the
cloud indicates large variability of the data points. This variability is larger for those
measurements that were taken after day 5.
It is important to notice that since the data set was taken from a patient that has
been under treatment for 14 days, the parameter estimates found are affected by the
treatment. For this reason, even though in Figure 31 the numerical solutions show
that patient 1 has no immune response, with the information we have we are not able
to claim that this is the case.
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Figure 31: Comparison of viral load data with model predictions. We fit HCV RNA
levels from a chronic HCV infected patient treated with interferon α− 2b from Neu-
mann et al.[19]. Numerical solutions of system given by equations (1)-(5) were calcu-
lated using the set of parameters given in Table 30. Initial conditions were chosen as
follows: T (0) = 1.0×106, I(0) = 2.0×105, V (0) = 2.5×106, Z(0) = 5.0×101,W (0) =
5.0× 100.
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5.2.2 Parameter Estimation for Patient 2
The model given by equations (1)-(5) is not exclusive for HCV infections. Other
type of viruses can also be understood through this model. As a matter of fact, data
from a hepatitis B infected patient during drug therapy was taken from Dahari et
al. [7] to fit the model and to estimate parameters and their corresponding standard
errors. As stated at the beginning of this section, a first iteration of the OLS method
with the genetic algorithm was run in MATLAB to find the point estimates for the
twelve parameters of the system. Initial conditions for the uninfected and infected
cells were also computed in the optimization process. With this set of parameter
estimates, called θˆ(0) in the bootstrap algorithm, we run 10,000 iterations to find new
parameter estimates with their corresponding standard errors. For this data set, we
obtained decent standard errors for ten out of the twelve parameters. For parameters
d and p that have standard errors that are larger than their estimation, only their
point estimates are shown on Table 14. Instead we use the abbreviation “t.l.n.r.”,
which stands for “too large not reported”. In other words, we do not report standard
errors with corresponding relative errors bigger than one.
Figure 32 shows the best fits solutions found with the bootstrap and the data
points. Just like for patient 1, the cloud tends to be thicker for those measurements
that were taken after day 5.
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Table 14: Bootstrap estimates and standard errors for patient 2
Parameter Bootstrap Estimate Standard Error (SE)
s 1.2025× 104 1.5652× 104
d 8.0000× 10−3 t.l.n.r.
β 9.3000× 10−3 2.9000× 10−3
a 7.7400× 10−2 3.0700× 10−2
p 4.8000× 10−3 t.l.n.r.
k 7.8300× 10−2 1.4900× 10−2
µ 4.9410× 10−1 3.0430× 10−1
q 1.6659× 10−4 9.9770× 10−5
c 3.0638× 10−7 7.1389× 10−8
b 3.5750× 10−1 2.3820× 10−1
g 6.6439× 10−7 8.7652× 10−7
h 7.2260× 10−1 1.5590× 10−1
Figure 32: Bootstrap cloud for patient 2. Running the bootstrap algorithm for 10,000
iterations a cloud of best fit solutions is plotted. Parameter estimates and standard
errors are calculated after the iterative process.
92
Figure 33: Comparison of viral load data with model predictions. We fit HBV DNA
levels from patient that was treated with pegylated interferon-2αa [7]. Numerical
solutions for patient 2 were calculated using the set of parameters given in Table 14.
Initial conditions were chosen as follows: T (0) = 7.0 × 105, I(0) = 9.7 × 104, V (0) =
5.5× 106, Z(0) = 50,W (0) = 5.
Figure 33 shows the data points and the numerical solutions of the system (1)-(5)
using the set of parameters shown in Table 14. Observations made for patient 1 are
also valid for patient 2. According to this figure and to the values of the estimates, this
looks to be an example of an endemic equilibrium with no immune response (second
equilibrium seen in Section 2). However, this could be misleading because the data set
is taken from a patient that has been under treatment and, as a consequence, some
parameters are affected. A possible approach to solve the problem of detecting a
difference between the parameters and the treatment that has been applied is solving
the inverse problem simultaneously with an optimal control problem. Nevertheless,
this process is computationally intensive.
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5.2.3 Parameter Estimation for Patient 3
HCV RNA levels from a patient treated with interferon α − 2b were taken from
Neumann et al.[19]. A first iteration of the OLS optimization method with the genetic
algorithm was run in MATLAB to find the point estimates for the twelve parameters of
the system. Initial conditions for the uninfected and infected cells were also computed
in the optimization process. With this set of parameter estimates, called θˆ(0) in
the bootstrap algorithm, we run 10,000 iterations of this method to find the new
parameter estimates and their corresponding standard errors. Point estimates and
their standard errors are summarized in Table 15. For those parameters with standard
errors that are larger than the estimation, only their point estimates are shown on
Table 15. Instead we use the abbreviation “t.l.n.r.”, which stands for “too large not
reported”.
Table 15: Bootstrap estimates and standard errors for patient 3
Parameter Bootstrap Estimate Standard Error (SE)
s 5.5687× 104 8.0768× 104
d 9.5042× 10−4 t.l.n.r.
β 5.0346× 10−4 t.l.n.r.
a 6.3480× 10−1 t.l.n.r.
p 9.7000× 10−3 t.l.n.r.
k 2.3581× 101 2.5610× 101
µ 3.4945× 100 1.2655× 100
q 1.8000× 10−3 8.3000× 10−3
c 1.0767× 10−7 8.2202× 10−7
b 1.1361× 100 1.4274× 100
g 6.8124× 10−7 t.l.n.r.
h 9.4230× 10−1 t.l.n.r.
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In Figure 34 the best fits found with the bootstrap and the data points were
plotted. The thickness of the cloud indicates large variability of the data points.
Figure 34: Bootstrap cloud for patient 3. Running the bootstrap algorithm for 10,000
iterations a cloud of best fit solutions is calculated to later compute the standard
errors.
Figure 35 shows the numerical solutions of the system (1)-(5) using the set of
parameters found in Table 15. It also shows the data set taken from [19]. According
to this figure and to the values of the estimates, this looks to be an example of an
endemic equilibrium with no immune response (second equilibrium seen in Section
2). However, this could be misleading because the data set is taken from a patient
that has been under treatment and as a consequence some parameters are affected. A
possible approach to solve the problem of making a difference between the parameters
and the treatment that has been applied could be solving the inverse problem along
with an optimal control problem. However this process is computationally intensive
and therefore out of our possibilities.
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Figure 35: Comparison of viral load data with model predictions. We fit HCV RNA
levels from patient that was treated with interferon-2αb [19]. Numerical solutions
for patient 3 were calculated using the set of parameters given in Table 15. Initial
conditions were chosen as follows: T (0) = 1.0 × 105, I(0) = 1.0 × 103, V (0) = 1.6 ×
107, Z(0) = 50,W (0) = 5.
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5.2.4 Parameter Estimation for Patient 4
Data from a hepatitis B infected patient during drug therapy was taken from
Dahari et al. [7]. A first iteration of the OLS method with the genetic algorithm
was run in MATLAB to find the point estimates for the twelve parameters of the
system. Initial conditions for the uninfected and infected cells were also computed
in the optimization process. With this set of parameter estimates, called θˆ(0) in the
bootstrap algorithm, we run 10,000 iterations to find new parameter estimates with
their corresponding standard errors. For this data set, we obtained decent standard
errors for all twelve parameters. Table 16 shows a summary of the parameter estimates
and their corresponding standard errors.
Table 16: Bootstrap estimates and standard errors for patient 4
Parameter Bootstrap Estimate Standard Error (SE)
s 9.0505× 103 2.7321× 103
d 9.4000× 10−3 1.4000× 10−3
β 6.6000× 10−3 1.2000× 10−3
a 1.7000× 10−2 4.0000× 10−3
p 1.1000× 10−3 1.5422× 10−4
k 3.8530× 10−1 8.3900× 10−2
µ 2.9267× 100 3.0380× 10−1
q 1.0000× 10−3 1.7529× 10−4
c 1.5526× 10−7 2.3676× 10−7
b 2.6030× 10−1 5.2600× 10−2
g 5.2049× 10−7 6.4187× 10−8
h 9.0200× 10−1 1.4810× 10−1
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In Figure 36, the best fits found with the bootstrap and the data points were
plotted. From this figure we can see how the data points in the second phase have
large variability compare to the first data points.
Figure 36: Bootstrap cloud for patient 4. Running the bootstrap algorithm for 10,000
iterations a cloud of best fit solutions is calculated to later compute the standard
errors.
Figure 37 shows the numerical solutions of equations (1)-(5) using the parameters
obtained in the bootstrapping and shown in Table 16. As explained in the previous
sections, due to the fact the data set is taken from a patient under treatment, we do
not have enough information to claim that there is not an immune response.
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Figure 37: Comparison of viral load data with model predictions. We fit HBV DNA
levels from a patient that was treated with adefovir dipivoxil [7]. Numerical solutions
for patient 4 were calculated using the set of parameters given in Table 16. Initial
conditions were chosen as follows: T (0) = 2.6 × 106, I(0) = 1.7 × 105, V (0) = 2.1 ×
107, Z(0) = 50,W (0) = 5.
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6 SENSITIVITY ANALYSIS PART II
The parameters estimates found in Section 5 were used to perform a sensitivity
analysis for each patient during transient and long-term phases. Just like in Section
3, we want to determine what are the most influential parameters in the behavior of
the viral load for patients that have been under treatment.
6.1 Sensitivity Analysis for Patient 1
For patient 1, we found that during treatment the parameters that are the most
influential are k, µ, and a. These are the natural production and natural decay of
viruses and the natural decay of infected cells, respectively. In fact, the larger the
values of k the larger the values of the viral load. Similarly, the larger the values of
the parameters µ and a, the smaller the values that V (t) will reach. Fig 38 shows the
relative sensitivities of V (t) in the transient phase. In Table 17, we have a summary
of the most influential parameters in the behavior of the viral load in the transient
phase.
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Figure 38: Numerical solutions of relative sensitivities θk
V
∂V
∂θk
for patient 1 in a transient
phase from 0 to 14
Table 17: Ranking of the most influential parameters for the viral load for patient
1 in the transient phase. During the period of time the patient is under treatment,
increasing parameter k will increase the viral load. Similarly, increasing the values of
parameters µ and a will produce a reduction in the number of virus particles.
Positive Negative
k µ
Parameter a
The simulation suggests that, in a longer time window (in the long-term phase),
the parameter s also becomes important in the behavior of V (t). As a matter of fact,
the sensitivity of s is as positive as the sensitivity of parameter k. See Figure 39 and
Table 18.
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Figure 39: Numerical solutions of relative sensitivities θk
V
∂V
∂θk
for patient 1 in a long-
term phase from 0 to 150
Table 18: Ranking of the most influential parameters in the viral load for patient 1 in
the long-term. The model suggests that in a long-term phase, increasing parameters
k and s will increase the viral load. Similarly, increasing the values of parameters µ
and a will produce a reduction in the number of virus particles.
Positive Negative
k µ
Parameter s a
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6.2 Sensitivity Analysis for Patient 2
According to Figure 40, the parameters that are most influential in the behavior
of V (t) for patient 2 are k, s in a positive manner and µ, a negatively. However, it
is important to mention that from t = 10 up to t = 25 the simulation suggests that
larger values of b would increase the viral load. This seems to be counterintuitive
since b is the rate of natural decay of CTLs. Table 19 shows a summary of the most
important parameters in the behavior of V (t) in the transient phase fr patient 2.
Figure 40: Numerical solutions of relative sensitivities θk
V
∂V
∂θk
for patient 2 in a transient
phase from 0 to 45
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Table 19: Ranking of the most influential parameters for the viral load for patient
2 in the transient phase. During the period of time the patient is under treatment,
increasing parameters b, k, and s will increase the viral load. Similarly, increasing
the values of parameters µ and a will produce a reduction in the number of virus
particles.
Positive Negative
b µ
Parameter k a
s
In Figure 41 we notice that, in the long-term the effect of b eventually becomes
irrelevant. In this figure is also shown that, parameters k and s are equally influential
in a positive manner. Likewise, parameters µ and a are equally influential in a negative
manner. Table 20 shows a summary of these results.
Table 20: Ranking of the most influential parameters for the viral load for patient 2 in
the long-term. The model suggests that in a long-term phase, increasing parameters
k and s will increase the viral load. Similarly, increasing the values of parameters µ
and a will produce a reduction in the number of virus particles.
Positive Negative
k µ
Parameter s a
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Figure 41: Numerical solutions of relative sensitivities θk
V
∂V
∂θk
for patient 2 in a transient
phase from 0 to 150
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6.3 Sensitivity Analysis for Patient 3
Sensitivities were computed for patient 3 using the estimates found in Section 5.
According to Figure 42, during the period of time the patient was under treatment
(transient phase), the parameters found to be the most influential were k, s in a pos-
itive manner and µ, a negatively. That is, increasing the proliferation of hepatocytes
and virus would make the viral load increase while the clearance rate of virus and
infected cells would make V (t) decrease. In Table 21, we have displayed the most
influential parameters in this phase.
Figure 42: Numerical solutions of relative sensitivities θk
V
∂V
∂θk
for patient 3 in a transient
phase from 0 to 14
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Table 21: Ranking of the most influential parameters for the viral load of patient
3 in a transient phase. During the period of time the patient is under treatment,
increasing parameters k, and s will increase the viral load. Similarly, increasing the
values of parameters µ and a will produce a reduction in the number of virus particles.
Positive Negative
k µ
Parameter s a
In the long-term phase the behavior of V (t) is still determined by the parameters
k, s, µ, and a. This is shown in Figure 43 and summarized in Table 22.
Figure 43: Numerical solutions of relative sensitivities θk
V
∂V
∂θk
for patient 3 in a long-
term phase from 0 to 150
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Table 22: Ranking of the most influential parameters in the viral load for patient 3 in
the long-term. The model suggests that in a long-term phase, increasing parameters
k and s will increase the viral load. Similarly, increasing the values of parameters µ
and a will produce a reduction in the number of virus particles.
Positive Negative
k µ
Parameter s a
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6.4 Sensitivity Analysis for Patient 4
A sensitivity analysis was done using the set of parameters estimated in Section
5 for patient 4. The numerical solutions shown in Figure 44 suggest that, at the
beginning of the treatment, the most influential parameters in the behavior of the
viral load are k and µ. However, for t > 5 parameters b and c play an important role
during the administration of treatment. These results are summarized in Table 23
that displays the most important parameters for the transient phase.
Figure 44: Numerical solutions of relative sensitivities θk
V
∂V
∂θk
for patient 4 in a transient
phase from 0 to 12
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Table 23: Ranking of the most influential parameters for the viral load of patient
4 in a transient phase. During the period of time the patient is under treatment,
increasing parameters k, and b will increase the viral load. Similarly, increasing the
values of parameters µ and c will produce a reduction in the number of virus particles.
Positive Negative
k µ
Parameter b c
Even though at the transient phase one would expect that parameters b and c
dominate among the other parameters, according to Figure 45, for t > 150, parame-
ters k, µ, s, and a become the most important in the long-term phase. These results
are summarized in Table 24.
Figure 45: Numerical solutions of relative sensitivities θk
V
∂V
∂θk
for patient 4 in a long-
term phase from 0 to 300
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Table 24: Ranking of the most influential parameters in the viral load for patient 4 in
the long-term. The model suggests that in a long-term phase, increasing parameters
b, k and s will increase the viral load. Similarly, increasing the values of parameters
c, µ and a will produce a reduction in the number of virus particles.
Positive Negative
b c
Parameter k µ
s a
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7 CONCLUDING REMARKS
In this thesis, we have used an existing model from [25] of ordinary differential
equations to describe the interaction between the responses of the human immune
system and a viral infection. In particular, in the context of the HCV infection, three
possible scenarios were studied, namely: dominant CTL response, dominant antibody
response, and coexistence.
In Section 2, by considering artificial values of parameters, a general illustration of
these scenarios was given. Each scenario can be characterized by stability conditions
given by the parameters. This conditions are studied deeply in [29].
Our first contribution to this study was a sensitivity analysis to determine the
most influential parameters in the behavior of the viral load. Transient and long-term
phases were explored with numerical simulations. In general in a transient phase, the
most influential parameters for dominant CTL response are k and µ. These are the
parameters of proliferation and natural decay of the viral load, respectively. For the
dominant antibody response scenario, we found that the most influential parameters
in the transient phase for the dominant antibody response scenario are also k and µ
and that this behavior eventually switches in the long-term phase. Ultimately, their
sensitivities converge to zero, and V(t) becomes affected only by parameters g and
h, the proliferation and dead rates of the antibodies, respectively. In Section 3.4, a
total counterintuitive behavior was observed in the sensitivities for the coexistence
scenario: the viral load is affected only by parameters g and h.
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Our second task in this thesis was to use optimal control theory to determine
optimal treatment strategies for each scenario mentioned above. We were able to
suggest treatment schedules that minimize the infection and the side effects of the
therapy in a finite time horizon. We conclude that if the goal of therapy is to reduce
the production of new virus and to reduce the production of infected cells, then
the dominant CTL response scenario seems to be more favorable than the dominant
antibody response and coexistence scenarios. However, in all the scenarios the viral
load and the number of infected cells rebound to pretreatment levels upon therapy
cessation.
Parameter estimates and standard errors were calculated by implementing the
OLS optimization method followed by the bootstrap method. Large variability was
observed in some of the parameter estimates. This variability can be explained in the
bootstrap cloud found for each data set (see Figures 30,32, 34, and 36). These clouds
have all the same behavior; large uncertainty for the data points in the second phase.
Because the parameter estimates are coming from data sets of patients that were
under treatment, it is not possible to use the conditions given in Section 2 to clas-
sify the dynamical system associated with each data set as dominant CTL, dominant
antibody, or coexistence. In fact, based on Figures 31,33,35, and 37, it seems these
systems settle into an endemic equilibrium without immune response. However, this
might not be the case. A possible approach to solve this issue involves the simul-
taneous solution of an optimal control and optimization problems which is a heavy
computationally intensive problem.
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A sensitivity analysis was done to understand what is the role of the estimated
parameters in the behavior of the state variable V (t) for data from 4 patients taken
from existing literature. As a result we can conclude that, in general, k and µ are the
most important parameters.
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